A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity

by Adam C Palmer, Christopher Chidley, Peter K Sorger
Published 2019-11-01

Pervasive selection for and against antibiotic resistance in inhomogeneous multistress environments

by Remy Chait, Adam C. Palmer, Idan Yelin, Roy Kishony
Published 2016-01-01

Modeling the impact of drug interactions on therapeutic selectivity

by Zohar B. Weinstein, Nurdan Kuru, Szilvia Kiriakov, Adam C. Palmer, Ahmad S. Khalil, Paul A. Clemons, Muhammad H. Zaman, Frederick P. Roth, Murat Cokol
Published 2018-08-01

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

by Yonghan He, Raphael Koch, Vivekananda Budamagunta, Peiyi Zhang, Xuan Zhang, Sajid Khan, Dinesh Thummuri, Yuma T. Ortiz, Xin Zhang, Dongwen Lv, Janet S. Wiegand, Wen Li, Adam C. Palmer, Guangrong Zheng, David M. Weinstock, Daohong Zhou
Published 2020-07-01